Core Scientific (CORZ) Leans On AI Infrastructure Growth, Is It Still Below Fair Value?
Core Scientific stock performance snapshot
Core Scientific (CORZ) has drawn fresh attention after recent trading left the stock roughly flat over the past month and down about 33% over the past 3 months, despite reporting year-on-year revenue and net income growth.
Core Scientific now trades at US$18.12, with a recent 7 day share price return of 5.72% contrasting with a 90 day share price decline of 33.38%. Meanwhile, the 1 year total shareholder return of 7.60% points to mixed but recovering momentum.
Compare Core Scientific's recent swings with a curated list of other crypto and blockchain infrastructure plays using our 21 cryptocurrency and blockchain stocks.
That mix of double digit yearly revenue and net income growth, a sharp 3 month share price drop, and a modest 1 year gain leaves Core Scientific at a crossroads. Does that tilt the balance of risk and reward toward potential buyers, or argue for more caution regarding valuation?
Most Popular Narrative: 51% Undervalued
Core Scientific's most followed valuation narrative pegs fair value at $37.13 per share, well above the recent $18.12 close. This puts the focus squarely on whether its AI infrastructure pivot can justify that gap.
Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12-year term, significantly boosting future revenue compared to their current levels. The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise.
See why 60 investors see Core Scientific as 51% undervalued.
Result: Fair Value of $37.13 (UNDERVALUED)
Still, Core Scientific's reliance on large counterparties like CoreWeave and the lingering uncertainty after Chapter 11 restructuring could quickly challenge that undervaluation story.
Find out about the key risks to this Core Scientific narrative.
Another view on Core Scientific valuation
The first narrative frames Core Scientific as roughly 51% undervalued, yet the current P/S ratio of 13.2x tells a different story. That is far above the US Software industry average of 3.8x and well above a fair ratio estimate of 6.1x, which points to meaningful valuation risk if expectations cool.
For investors comparing story versus sticker price, the gap between the current 13.2x P/S and a 6.1x fair ratio raises a simple question: Is Core Scientific priced for more AI and HPC success than you are comfortable assuming, or not yet enough?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Core Scientific is split, which is exactly why it pays to look through the numbers yourself and decide where you stand. To weigh both sides of that debate, start with the 1 key reward and 3 important warning signs.
Looking for more Core Scientific investment ideas?
If Core Scientific has your attention but you want a wider watchlist, use the Simply Wall Street Screener to explore other opportunities as part of your own research process.
- Target quality at a discount by scanning a curated set of stronger fundamentals and pricing with the 30 high quality undervalued stocks.
- Prioritize resilience by focusing on companies with healthier finances using the list of solid balance sheet and fundamentals (23 results).
- Hunt for overlooked potential by reviewing financially robust outliers through the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com